Introduction: Self-assembling
peptides are synthetic, amphipathic
peptides that may serve as new
hemostatic agents. The first-generation hemostat
TDM-621 has been used in clinical practice in a limited capacity. The second-generation hemostat TDM-623 was developed for faster gel formation and better tissue-sealing capability. We compared the physical properties and
hemostatic effects of
TDM-621 and TDM-623.Material and methods: First, we evaluated the physical properties of both materials in a bench test setting, including the external appearance of the gel, rheological properties in
sol/gel forms, and local self-weight pressure. We then performed a randomized preclinical trial using swine.
Bleeding wounds were created on the liver surface, and randomized application of 1 mL of either
TDM-621 or TDM-623 was performed. The
hemostatic effects were evaluated two and five minutes after application. Resected specimens were histologically evaluated.Results: In the bench test setting, TDM-623 showed higher gel height, higher
sol viscosity, and higher local self-weight pressure than
TDM-621. In the preclinical setting, TDM-623 showed significantly greater
hemostatic effects at two and five minutes after application than
TDM-621. Histological examination showed no inflammatory reaction in either group.Conclusions: TDM-623 has greater
hemostatic capability than
TDM-621 and is therefore promising as a new
hemostatic agent.